Vaginal dryness after menopause is not a small thing that passes. It is the most visible symptom of a condition with a proper name — genitourinary syndrome of menopause (GSM) — and its defining feature is the one nobody tells you: it is progressive. Hot flushes usually burn out after a few years. GSM does the opposite. Left alone, the tissue keeps thinning and the symptoms keep creeping — dryness, burning, itching, painful sex, urinary urgency, and infections that keep coming back. The single most effective treatment, low-dose vaginal estrogen, is also the one women most often refuse out of fear of "hormones" — and that fear, in this specific case, is largely misplaced.
What is actually happening to the tissue?
Estrogen is what keeps the vaginal and vulvar tissue plump, elastic and self-lubricating. When it falls at menopause, a chain of changes follows, and each link explains a different symptom:
- The epithelium thins. The vaginal lining loses cell layers and rugae (the folds that let it stretch). Thin tissue tears and burns more easily — hence pain at penetration, and sometimes spotting afterwards.
- Blood flow drops. Lubrication in response to arousal is a transudate that comes from blood vessels in the vaginal wall. Less blood flow means less natural wetness, and it is slower to arrive.
- Glycogen falls. Estrogen loads the surface cells with glycogen, which is food for Lactobacillus. Less glycogen means fewer lactobacilli, less lactic acid, and a rise in vaginal pH from roughly 4 to well above 5.
- The microbiome shifts. A less acidic vagina is friendlier to gut bacteria such as E. coli. That is why recurrent urinary tract infections cluster in exactly this group of women, and why bladder and urethral symptoms belong to the same syndrome.
That last point is the reason the name changed. "Vaginal atrophy" was too narrow: the urethra and bladder trigone are estrogen-sensitive too. GSM covers the whole territory — genital, sexual and urinary — which is why the 2025 guideline was written jointly by the American Urological Association, SUFU and the American Urogynecologic Society rather than by gynaecologists alone. For the full picture of the syndrome, see our guide to genitourinary syndrome of menopause.
How common is it — and why does almost nobody get treated?
The 2025 AUA/SUFU/AUGS guideline puts prevalence at roughly 27% to 84% of postmenopausal women. The band is wide because studies ask the question differently, not because there is real doubt that this is common — it is. The guideline is also clear about the asymmetry that matters: symptoms such as vulvovaginal dryness increase with advancing age, while hot flushes and night sweats fade.
The treatment gap is worse than the diagnosis gap. In the REVIVE survey of US postmenopausal women with symptoms, almost half had never discussed them with a clinician; among those who had, the clinician was the one who raised the subject only 13% of the time; 62% were unfamiliar with the condition as a medical diagnosis at all; and only about 40% were using any treatment specific to it, mostly bought over the counter. So you have a progressive, treatable condition in which the patient waits for the doctor to ask and the doctor waits for the patient to complain. Years pass. Tissue does not wait.
Practical consequence: you may have to raise it yourself, and you may have to raise it twice. Our menopause doctor report builds a one-page symptom summary you can hand over, which makes the conversation shorter and harder to brush past.
Moisturiser or lubricant? They are not the same product
This distinction is genuinely useful, and women buy the wrong one constantly.
- A vaginal moisturiser is used on a schedule — typically every few days, regardless of whether you are having sex. It adheres to the vaginal wall and rehydrates tissue over time. It treats dryness. Using it only before sex wastes it.
- A lubricant is used at the moment, to reduce friction during sex. It does nothing for the underlying tissue and is not intended to.
Many women try a lubricant, find it does not fix the burning and itching they feel on an ordinary Tuesday afternoon, and conclude that nothing works. In fact they were using a product designed for a different job. Both are legitimate, and the guideline recommends them — alone or alongside other therapies — for dryness and painful sex. We compare products in vaginal moisturisers and lubricants for menopause dryness.
Two things worth knowing: oil-based lubricants degrade latex condoms, and glycerin-heavy or high-osmolality products can irritate already-fragile tissue in some women. If a product stings, that is information — switch, do not persevere.
Which treatments actually work? An honest comparison
| Treatment | What it does | Evidence | Honest verdict |
|---|---|---|---|
| Vaginal moisturisers | Rehydrate tissue when used regularly, not just before sex | Moderate recommendation | Real benefit for mild-to-moderate dryness. Non-hormonal, no prescription. Will not reverse tissue thinning. |
| Lubricants | Reduce friction during sex, at the time | Moderate recommendation | Effective for the specific job they do. Not a treatment for the condition itself. |
| Low-dose vaginal estrogen (cream, tablet, ring, gel) | Restores epithelium, blood flow, glycogen and acidic pH | Strong recommendation — the highest grade in the guideline | The most effective option. Works locally, where systemic HRT often does not fully. Minimal systemic absorption. |
| Vaginal DHEA (prasterone) | Precursor hormone converted locally to estrogen and androgen inside vaginal cells | Moderate recommendation | Genuinely effective for dryness and painful sex; an alternative worth discussing if estrogen is unwanted or not tolerated. |
| Ospemifene (oral SERM) | Estrogen-like action on vaginal tissue, taken as a daily tablet | Conditional recommendation | Works, and suits women who do not want anything vaginal. But it is systemic, and its US label still carries a boxed warning (endometrial cancer and cardiovascular disorders). |
| Vaginal estrogen for recurrent UTIs | Restores the lactobacilli-dominant, acidic environment that resists E. coli | Moderate recommendation — and, at Grade B, better-quality evidence than most of the guideline | Well evidenced and badly under-used: many women are cycled through repeat antibiotics instead. |
| CO2 laser, Er:YAG laser, radiofrequency ("vaginal rejuvenation") | Marketed as tissue remodelling | Evidence does not support use — the guideline says clinicians should counsel patients accordingly | Expensive, rarely covered, and not backed by the evidence. Not a first line, not a second line. |
| Systemic HRT alone | Treats hot flushes, night sweats, bone loss | Effective for vasomotor symptoms | Frequently not enough for genitourinary symptoms — a substantial minority of women on systemic HRT still need local treatment as well. |
Is vaginal estrogen safe? The part that matters most
This is where most women get stuck, so it deserves plain language.
Low-dose vaginal estrogen is not systemic HRT. The dose is small, it acts on the tissue it touches, and systemic absorption is minimal — serum levels generally stay within the postmenopausal range. That is not marketing; it is the basis on which the major bodies now advise that a progestogen is not required alongside it to protect the uterus, and that endometrial surveillance should not be performed simply because a woman is using low-dose vaginal estrogen, vaginal DHEA or ospemifene. In practice it is generally considered suitable for many women who cannot, or do not want to, take systemic hormones.
On breast cancer, the 2025 guideline is explicit that there is an absence of evidence linking low-dose vaginal estrogen to the development of breast cancer, and that for women with a history of breast cancer it may be recommended through multidisciplinary shared decision-making — a conversation to have with your oncology team, not a door that is automatically closed.
The regulatory picture moved too. On 10 November 2025 the FDA initiated the removal of the boxed-warning statements on cardiovascular disease, breast cancer and probable dementia from estrogen-containing menopausal hormone products, on the grounds that a warning derived largely from one systemic formulation in the Women's Health Initiative had been applied indiscriminately to every estrogen product regardless of dose or route — vaginal preparations included. The first approved labels followed on 12 February 2026: six products spanning all four categories of menopausal hormone therapy, one of them a topical vaginal estrogen. Other manufacturers are still working through the process, so the leaflet in the box you buy today may lag the science. The boxed warning about endometrial cancer for systemic estrogen-alone products was kept. We covered the decision and its limits in the FDA boxed-warning removal, and the treatment itself in depth in vaginal estrogen.
None of this means it is right for everyone, and none of it is a reason to change what you are taking on your own. It means the reflex "I can't take hormones, so nothing can be done" is usually wrong, and it has kept women in pain for years. Ask; do not assume.
What about the recurrent UTIs?
If you are postmenopausal and getting UTI after UTI, this is the connection nobody made for you. Restoring the vaginal environment restores its defences. In the classic randomised trial — Raz and Stamm, New England Journal of Medicine, 1993 — postmenopausal women with recurrent UTIs were given intravaginal estriol cream or placebo; infections fell to 0.5 episodes per patient-year on estriol versus 5.9 on placebo, vaginal pH dropped, and lactobacilli reappeared. Later trials and pooled analyses have supported the effect, and the 2025 guideline now specifically recommends local vaginal estrogen for women with GSM and recurrent UTIs to reduce future infections.
Yet the usual pathway is another antibiotic, and another. If that is your pattern, it is worth asking whether vaginal estrogen has been considered. See UTI prevention and bladder changes in menopause.
How long until anything works?
Set expectations honestly. Lubricants work instantly, because they are physics, not biology. Moisturisers usually take a few weeks of regular use to shift background dryness. Local hormonal treatments work on tissue-repair timescales — improvement over several weeks, with fuller benefit over a few months — and because GSM is progressive, benefit is generally maintained only while treatment continues. Stopping usually means the tissue drifts back. That is not a marketing trick; it is the same logic as blood-pressure medication. You can compare typical timelines with our how long until it works tool.
When to see a doctor
Book an appointment — do not self-treat and wait — if any of the following apply:
- Any bleeding after menopause. This is postmenopausal bleeding and always needs evaluation, including bleeding after sex, or spotting you can explain away as "just dryness". Most causes are benign; a minority are endometrial cancer, which is highly treatable when caught early. This is the single non-negotiable item on this page. See postmenopausal bleeding.
- Sex is painful, not just dry. Pain deserves its own assessment — see painful sex in menopause — and can involve the pelvic floor as well as the tissue.
- Repeated UTIs, or urinary urgency and burning that keep returning.
- Unusual discharge, odour, sores, lumps, white patches or persistent itching. These are not GSM by default: infection and vulvar skin conditions such as lichen sclerosus need diagnosis, not moisturiser.
- Over-the-counter measures have not helped after a few weeks, or symptoms are affecting your sleep, exercise, relationship or mood. That is a sufficient reason on its own.
If you already take other medicines, run any new product past a pharmacist or use our interaction checker — ospemifene in particular has drug interactions and is not appropriate for everyone.
The bottom line
Vaginal dryness in menopause is a diagnosable, progressive, treatable condition — and the reason it goes untreated is not that treatment is unavailable, but that the conversation never happens. Moisturisers and lubricants are useful and non-hormonal. Local vaginal estrogen is the most effective option, does not behave like systemic HRT, and additionally reduces recurrent UTIs. Lasers are not supported by the evidence. And any bleeding after menopause gets seen, every time.
This article is for information, not medical advice. It does not recommend starting, stopping or changing any medication. Doses and choice of product are decisions for you and your clinician. Explore more in our menopause hub.
